Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-30

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this interventional study is to validate the strategy of adjuvant therapy with dendritic cells in HIV infection in chronically infected individuals. The main questions it aims to answer are related to the safety and tolerance of the intervention and the virological and immunological impact of immunotherapy with aDC1 in HIV-infected individuals. The study will include 30 diagnosed HIV-infected patients, using antiretroviral therapy, who will be immunized with aDC1 or placebo according to the arms of this study: G1) placebo; G2) aDC1immunization; G3) aDC1 immunization with analytical treatment interruption of ART.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus

NCT02766049

HIV Infection

COMPLETED PHASE1/PHASE2

A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects

NCT00833781

HIV-1 Infection HIV Infections

COMPLETED PHASE1/PHASE2

Dendritic Cell Vaccine in HIV-1 Infection

NCT00402142

HIV Infections

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients

NCT02767193

HIV Infection

COMPLETED PHASE1

Autologous Dendritic Cell Vaccine in HIV1 Infection

NCT00510497

HIV Infections

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dendritic cell based immunotherapy is a potential tool to stimulate a specific immune response, as a complementary treatment for HIV-infected individuals using ART. Polarizing DCs are capable to produce high levels of IL-12p70 and induce a strong cytotoxic response that is very useful in viral infections. In this context, we propose to study aDC1 pulsed with relevant HIV peptides for treatment of HIV infected individuals.

The study will include 30 diagnosed HIV-infected patients, using antiretroviral therapy, who will be immunized with aDC1 or placebo according to the arms of this study: G1) placebo; G2) aDC1immunization; G3) aDC1 immunization with analytical treatment interruption of ART. Autologous PBMCs will be collected for baseline parameters and vaccine will be inoculated in 3 doses (with 4 week interval). Three weeks after 3th vaccine inoculation, patients will be followed for 6 months and blood and biopsis samples will be collected for different parameters measurement as immune activation, immunogenicity, humoral response, mucosal cellular immunity and virologic profile and viral reservoir analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Phase I, double-blind, randomized study with three parallel groups as follows: : G1) placebo; G2) aDC1immunization; G3) aDC1 immunization with analytical treatment interruption of ART.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

To avoid bias in evaluating the results, the research volunteer and the team that will perform the application of the vaccine product will be blind in the present study. The team responsible for coordinating the project will not be blind.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

The participants will receive a placebo, which is the excipient solution of aDC1 cell suspension consisting of a commercial ringer´s lactate solution.

Group Type PLACEBO_COMPARATOR

Commercial ringer´s lactate solution

Intervention Type OTHER

Placebo

aDC1immunization

The participants will be immunized with aDC1 unpulsed with HIV peptides.

Group Type ACTIVE_COMPARATOR

Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides

Intervention Type BIOLOGICAL

Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides

aDC1 immunization with analytical treatment interruption of ART

The participants will be immunized with aDC1 pulsed with HIV peptides.

Group Type EXPERIMENTAL

Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides

Intervention Type BIOLOGICAL

Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides

Intervention Type BIOLOGICAL

Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides

Intervention Type BIOLOGICAL

Commercial ringer´s lactate solution

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV infection confirmed according to the criteria of the Department of Chronic Diseases and Sexually Transmitted Infections of the Brazilian Health Ministry;
* Absence of the use of antineoplastic or corticosteroid therapies for a minimum period of six months prior to study entry;
* Absence of comorbidities considered uncontrolled by researchers;
* Viral load ≤ 40 copies/mL, stable (i.e., no \> 0.5 log) in the six months prior to the start of the study;
* Blood count of CD4 T lymphocytes ≥ 500 cells/μL, stable (i.e., \>25%) in the six months prior to the start of the study;
* Informed consent

Exclusion Criteria

* Individuals without adequate venous access to the blood collection and apheresis procedure;
* Use of drugs or alcohol in a way that interferes with patients' ability to follow the study requirements;
* Pregnancy, breastfeeding or interest in becoming pregnant during the study period;
* Presence of any other condition that, in the evaluation of researchers is able to promote alteration of the immune system, as well as any disorders that could affect understanding in the process of informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No